News articles about Albireo Pharma (NASDAQ:ALBO) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Albireo Pharma earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.9840895185994 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- BRIEF-Albireo Reports Fourth Quarter And Year-End 2017 Financial Results (reuters.com)
- Albireo Pharma (ALBO) Now Covered by Analysts at Needham & Company LLC (americanbankingnews.com)
- Albireo Pharma (ALBO) Releases Earnings Results, Beats Expectations By $0.23 EPS (americanbankingnews.com)
- What analyst predict for Agenus Inc NASDAQ:AGEN And Albireo Pharma Inc NASDAQ:ALBO ? (stockmarketdaily.co)
- Albireo Pharma, Inc. to Host Earnings Call (finance.yahoo.com)
Albireo Pharma (NASDAQ ALBO) traded down $1.00 on Friday, hitting $35.49. 39,345 shares of the company were exchanged, compared to its average volume of 79,369. Albireo Pharma has a 1-year low of $15.31 and a 1-year high of $39.87.
A number of research analysts have recently weighed in on the company. Needham & Company LLC assumed coverage on Albireo Pharma in a research note on Thursday. They issued a “buy” rating and a $50.00 price target on the stock. BidaskClub cut shares of Albireo Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, February 22nd. ValuEngine upgraded shares of Albireo Pharma from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research cut shares of Albireo Pharma from a “hold” rating to a “sell” rating in a research report on Wednesday, January 24th. Finally, Wedbush restated a “buy” rating on shares of Albireo Pharma in a research report on Friday, January 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $58.25.
In other Albireo Pharma news, major shareholder Phase4 Partners Ltd sold 100,000 shares of the stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $34.44, for a total transaction of $3,444,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Life Sciences Maste Perceptive bought 275,000 shares of the stock in a transaction on Thursday, January 25th. The shares were purchased at an average price of $33.00 per share, with a total value of $9,075,000.00. The disclosure for this purchase can be found here. 22.30% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This report was originally published by BBNS and is the sole property of of BBNS. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://baseballnewssource.com/2018/03/16/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-albireo-pharma-albo-stock-price/1988111.html.
About Albireo Pharma
Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.